CAP TODAY and the Association for Molecular Pathology have teamed up to bring molecular case reports to CAP TODAY readers. AMP members write the reports using clinical cases from their own practices that show molecular testing’s important role in diagnosis, prognosis, and treatment. The following report comes from the University of Wisconsin School of Medicine and Public Health. For more information about the AMP and all previously published case reports, visit www.amp.org.
Nea Fride, MD
Matthew Contreras, MD
William M. Rehrauer, PhD
November 2026—Acute myeloid leukemia (AML) is a rapidly progressing and life-threatening hematologic malignancy characterized by the clonal expansion of immature myeloid cells (“blasts”) in the bone marrow, peripheral blood, and occasionally extramedullary tissues. The disruption of hematopoietic processes, such as erythropoiesis and megakaryopoiesis, can result in clinically significant cytopenias and subsequent bone marrow failure. The overall prognosis is poor, with a five-year survival rate estimated to be around 39 percent.1
AML is a genetically complex and heterogeneous disease, with numerous subtypes defined by cytogenetic and molecular abnormalities.2 FMS-like tyrosine kinase 3 (FLT3) is one of the most frequently mutated and clinically significant genes, implicated in about 30 percent of AML cases.3 FLT3 is expressed on hematopoietic progenitors and plays a crucial role in cell survival, proliferation, and differentiation. Two primary classes of activating FLT3 mutations are found in AML cases: internal tandem duplications (FLT3-ITD) and tyrosine kinase domain point mutations (FLT3-TKD). FLT3-ITD mutations occur within the juxta-membrane domain and lead to constitutive receptor activation, promoting unregulated cell proliferation, anti-apoptosis, and impaired differentiation via aberrant activation of downstream STAT5, MAPK, and AKT pathways. These mutations are associated with a higher leukemic burden, increased relapse risk, and a dismal prognosis. In contrast to duplications, FLT3-TKD mutations most commonly occur as point mutations at codons D835 or I836 within the activation loop of the kinase domain. While these mutations also result in constitutive receptor activation, they are associated with a more variable impact on prognosis. Proper identification of FLT3 mutations in AML cases is essential not only for prognostic assessment but also for treatment selection and disease monitoring (Fig. 1).

Case. An 83-year-old female with acute myeloid leukemia in remission on maintenance azacitidine and venetoclax chemotherapy presented to the emergency department with sudden painless vision loss. She had recent illnesses that caused her to miss her maintenance chemotherapy. She was found to have an elevated erythrocyte sedimentation rate and thrombocytopenia, prompting a clinical workup for stroke, giant cell arteritis, and recurrent malignancy, as well as a recent syncopal episode. Magnetic resonance imaging demonstrated cauda equina nerve root enhancement, as well as heterogeneous marrow signal with pathologic enhancement of three vertebral bodies suggestive of leukemic involvement. A subsequent lumbar puncture with flow cytometry demonstrated recurrent acute myeloid leukemia (Fig. 2). The patient was transferred to the hematology service and a bone marrow biopsy (Fig. 3) was procured on the same day. By this point the patient had vocal cord paralysis also attributed to leukemic involvement.


As presented in Fig. 4, initial bone marrow testing displayed a weak positive FLT3-ITD mutation detected in the specimen (approximately one percent blasts). This fell below the limit of detection of the assay (ITD ratio: 0.0031; variant frequency: 0.31 percent) but was reproducible. The bone marrow specimen was subpar due to the low cellularity, but there was a high leukemic burden in the CSF specimen (Figs. 2 and 3). An associate physician suggested FLT3 testing on the CSF sample. Most clinical laboratories, including Mayo5 and ARUP,6 do not offer CSF testing of FLT3. Our laboratory also does not test for FLT3 on a CSF specimen, but the test was performed owing to the uniqueness of this case. The CSF testing demonstrated a significantly greater level of blasts than the patient’s marrow. Subsequently, the same size ITD was detected in the CSF collected on the same day as the bone marrow (Fig. 4) but at a much higher frequency (ITD ratio: 0.82; variant frequency: 45 percent). Neither the bone marrow nor the CSF demonstrated a TKD mutation in codons 835 or 836.

Discussion. The FLT3-ITD mutation found in this patient is associated with a higher leukemic burden, increased relapse risk, and a dismal prognosis. Since cerebrospinal fluid is not a validated sample type for our FLT3 testing, we reported the low-level FLT3 result detected in the bone marrow with a comment that its presence was verified by detecting the same ITD at a much greater level in the CSF. This clinically correlates with low-level residual disease in the marrow but a central nervous system (CNS) relapse of AML.
CNS relapse in AML is rare, but it is prognostically extremely unfavorable and associated with very high mortality rates. Notably, FLT3-mutated AML showed a high propensity for CNS relapse with a cumulative incidence of 50 percent in one study.7 Directed therapy in CSF is usually performed in the form of intrathecal chemotherapy. Treatment options include FLT3 inhibitors such as midostaurin (Rydapt), gilteritinib (Xospata), or quizartinib (Vanflyta). The CNS penetration of any of these FLT3 inhibitors is variable, and often a combination of systemic and intrathecal chemotherapy is required.8 Although this patient received only intrathecal chemotherapy of methotrexate and hydrocortisone, due to the aggressive nature of this malignancy the family and patient transitioned to palliative care.
This case underscores the clinical significance of a common hematologic malignancy driven by therapeutically targetable genetic mutations. However, the absence of validated CSF testing for FLT3 mutations presents a critical limitation in the molecular evaluation of AML, particularly in rare cases involving CNS relapse. As demonstrated here, reliance solely on bone marrow analysis may underestimate disease burden and delay appropriate therapeutic interventions.
- Albuquerque KMC, Joventino CB, Moreira LC, et al. Clinical outcome and prognosis of patients with acute myeloid leukemia submitted to chemotherapy with 5 years of follow-up. Hematol Transfus Cell Ther. 2024;46(1):8–13.
- Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345–1377.
- Kiyoi H, Kawashima N, Ishikawa Y. FLT3 mutations in acute myeloid leukemia: therapeutic paradigm beyond inhibitor development. Cancer Sci. 2020;111(2):312–322.
- Murphy KM, Levis M, Hafex MJ, et al. Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay. J Mol Diagn. 2003;5(2):96–102.
- FLT3 mutation analysis, varies. Mayo Clinic Laboratories. www.mayocliniclabs.com/test-catalog/overview/19739#Specimen
- FLT3 ITD and TKD mutation detection. ARUP Laboratories. https://ltd.aruplab.com/Tests/Pub/3001161
- Kouidri K, Acker F, Toenges R, et al. Central nervous system relapse after allogeneic HCT in FLT3-mutated AML. Ann Hematol. 2024;103(12):5387–5393.
- Suárez EU, Castaño-Bonilla T, Salgado R, Solán L, Lázaro-García A, Alonso-Domínguez JM. Therapeutics of acute myeloid leukemia with central nervous system involvement. Clin Hematol Int. 2025;7(1):40–46.
Dr. Fride and Dr. Contreras are residents (PGY-3) and Dr. Rehrauer is associate professor and director of molecular diagnostics—all in the Department of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, Madison.
Test yourself
Here are three questions taken from the case report. Answers are online now at www.amp.org/casereports and will be published next month in CAP TODAY.
1. FDA-approved companion diagnostic FLT3 testing at this time is validated and approved on all of the below samples except:
a. Bone marrow.
b. Blood.
c. CSF.
d. All are acceptable.
2. Which of the following mutations most commonly occurs as a point mutation in the activation loop of tyrosine kinase?
a. FLT3-ITD.
b. FLT3-TKD.
c. FLT3-WT.
d. FLT3-ITD and FLT3-TKD.
3. FLT3-mutated acute myeloid leukemia shows a propensity for relapse in what system?
a. Cardiopulmonary.
b. Central nervous system.
c. Gastrointestinal.
d. Integumentary.